PSMD2

Across TCGA pan-cancer cohorts, PSMD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMD2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSMD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where PSMD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.641	0.907	.001	37	view →
PDAC	OS	Tertile	All	0.748	0.900	.011	14	view →
CCRCC	OS	Median	All	0.909	1.000	.019	4	view →
HNSC	OS	Median	III,IV	1.000	0.948	.043	3	view →
GBM	DFS	Median	All	0.295	0.446	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMD2–LUAD (OS)

Open the LUAD breakdown →